144 ·Filed Mar 30, 2026

PGEN

PRECIGEN, INC.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago SEC0001968582-26-000339
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sales via Form 4 filings; while the proposed sale is material in size, it reflects planned or routine disposition by a long-term holder rather than a sudden negative signal. Given Kirk’s history with the company (former Intrexon), this may be part of estate or portfolio planning.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
PGEN ▲ +51.42% at T+60d
NEUTRAL call ✓ call won +51.42% · α vs SPY +39.04% · entry $3.87 → $5.86
Entry anchored
Mar 30, 03:59 PM ET
via exchange tick
T+1d
+1.55%
call +1.55% · α +0.80%
$3.93
settled 6mo ago
T+5d
+6.46%
call +6.46% · α +2.52%
$4.12
settled 6mo ago
T+20d
+6.20%
call +6.20% · α -3.22%
$4.11
settled 5mo ago
T+60d
+51.42%
call +51.42% · α +39.04%
$5.86
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Randal J. Kirk, a director and 10% shareholder of Precigen, has filed a Form 144 to propose the sale of 4,814,072 shares, primarily through affiliated trusts and LLCs. The filing signals intent to sell but does not confirm execution, and it involves long-held shares acquired via private placements, service agreements, and vesting events.

Key Facts

  • Reporting owner: Randal J. Kirk, Director and 10% shareholder of Precigen, Inc.
  • Total shares proposed for sale: 4,814,072
  • Shares to be sold by multiple affiliated entities including trusts and LLCs (e.g., R.J. Kirk Declaration of Trust, Sunset 2020 LLC, JPK and MGK family LLCs)
  • Shares were acquired over time through private placements (2013–2018), RSU vesting, and service agreements
  • Filing date: March 30, 2026; agent: J.P. Morgan Securities LLC

Financial Impact

Approximately $48.1 million based on PGEN's current market price of ~$10 per share (4.8M shares × $10)

insider ownershippotential dilutionshare float

Risk Factors

  • Potential downward pressure on stock if sales are executed rapidly
  • Perception of insider lack of confidence, especially if no prior pattern of sales exists

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001968582-26-000339
Document: 0001968582-26-000339-index.html0001968582-26-000339
Document: 0001968582-26-000339.txt0001968582-26-000339
12 reports for PGEN
Performance horizon
100% Hit rate 3 of 3 directional calls best @ T+60▲ +52.17%May 13, 2026
Filters
Rows
Reports for PGEN — sortable, filterable
TypeNow
Aug 29, 2026
4w ago
Insider Cluster
NEUTRAL ★ 3/10
$6.93 $7.94▲ +14.57%▲ +14.51%$8.30 (+19.70%)
Aug 26, 2026
5w ago
144
NEUTRAL ★ 3/10
$7.19 $7.70▲ +7.09%▲ +7.60%$8.30 (+15.37%)
Aug 25, 2026
5w ago
Insider Cluster
BEARISH ★ 4/10
$7.42 $7.70▼ −3.77%▼ −3.55%$8.30 (−11.79%)
Aug 25, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.42 $7.70▲ +3.77%▲ +3.55%$8.30 (+11.79%)
Aug 7, 2026
7w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.00 $6.87▼ −1.86%▼ −0.94%$8.30 (+18.50%)
Aug 3, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$6.53 $6.86▲ +5.05%▲ +6.29%$8.30 (+27.03%)
Jul 1, 2026
13w ago
Insider Cluster
BEARISH ★ 5/10
$5.64 $5.94▼ −5.32%▼ −5.73%$8.30 (−47.07%)
Jun 24, 2026
14w ago
8-K
NEUTRAL ★ 3/10
$5.52 $5.54▲ +0.36%▼ −0.17%$8.30 (+50.27%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.86 $5.25▲ +36.01%▲ +37.58%$8.30 (+114.90%)
Jun 1, 2026
17w ago
Insider Cluster
NEUTRAL ★ 3/10
$3.86 $5.25▲ +36.01%▲ +37.58%$8.30 (+114.90%)
Showing 10 of 12

US Market Status

Market Open — Closes in 3h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access